Programmed Cell Death after Intracerebral Hemorrhage
| Autor: | Anatol Manaenko, Petra Burkardt, Hagen B. Huttner, Tobias Bobinger |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Cell death
0301 basic medicine Programmed cell death Necrosis Bioinformatics Article necrosis 03 medical and health sciences 0302 clinical medicine Hematoma medicine Animals Humans Pharmacology (medical) cardiovascular diseases Cerebral Hemorrhage Pharmacology Intracerebral hemorrhage ICH business.industry pyroptosis apoptosis Pyroptosis General Medicine medicine.disease intracerebral hemorrhage nervous system diseases Clinical trial Psychiatry and Mental health 030104 developmental biology Blood pressure Neurology Apoptosis Anesthesia Neurology (clinical) medicine.symptom business 030217 neurology & neurosurgery |
| Zdroj: | Current Neuropharmacology |
| ISSN: | 1570-159X |
| DOI: | 10.2174/1570159x15666170602112851 |
| Popis: | Background: Intracerebral hemorrhage (ICH) accounts for up to 15% of all strokes and is characterized by high rates of mortality and morbidity. The post-ICH brain injury can be distinguished in 1) primary, which are caused by disrup-tion and mechanical deformation of brain tissue due to hematoma growth and 2) secondary, which are induced by microglia activation, mitochondrial dysfunction, neurotransmitter and inflammatory mediator release. Although these events typically lead to necrosis, the occurrence of programmed cell death has also been reported after ICH. Methods: We reviewed recent publications describing advance in pre- and clinic ICH research. Results: At present, treatment of ICH patients is based on oral anticoagulant reversal, management of blood pressure and other medical complications. Several pre-clinical studies showed promising results and demonstrated that anti-oxidative and anti-inflammatory treatments reduced neuronal cell death, however, to date, all of these attempts have failed in randomized controlled clinical trials. Yet, the time frame of administration may be crucial in translation from animal to clinical studies. Furthermore, the latest pre-clinical research points toward the existence of other, apoptosis-unrelated forms kinds of pro-grammed cell death. Conclusion: Our review summarizes current knowledge of pathways leading to programmed cell death after ICH in addition to data from clinical trials. Some of the pre-clinical results have not yet demonstrated clinical confirmation, however they sig-nificantly contribute to our understanding of post-ICH pathology and can contribute to development of new therapeutic ap-proaches, decreasing mortality and improving ICH patients’ quality of life. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|